Base de dados : MEDLINE
Pesquisa : D27.505.696.068 [Categoria DeCS]
Referências encontradas : 564 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 57 ir para página                         

  1 / 564 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29386439
[Au] Autor:Shimauchi A; Naganuma M; Sasaoka S; Hatahira H; Motooka Y; Hasegawa S; Fukuda A; Nakao S; Sakai C; Yokoyama S; Ino Y; Nakamura M; Iguchi K
[Ad] Endereço:Laboratory of Community Pharmacy, Gifu Pharmaceutical University.
[Ti] Título:[Survey of Description on Package Inserts of OTC Drugs].
[So] Source:Yakugaku Zasshi;138(2):259-267, 2018.
[Is] ISSN:1347-5231
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo: The "self-medication tax deduction" system began in Japan in January 2017, allowing people to encourage the use of OTC drugs. Package inserts contain important information for consumers regarding their use. In this study, we first checked whether the items, as required in the notifications of the Japanese Ministry of Health, Labour and Welfare, are described in the package inserts of cold remedies and analgesic antipyretics in OTC drugs. The descriptions of almost all packages checked in this study were based on the notifications, but those of a small number of them were not. Next, we examined the description of the items, unrequired in the notification, but worthy for proper use of drugs; e.g., the description of prohibition for use by "patients with severe hypertension" in case of ibuprofen-containing products, and the description was found in only seven of 180 products. Manufactures should make package inserts along with notifications, including the description for proper use of drugs.
[Mh] Termos MeSH primário: Serviços de Informação sobre Medicamentos
Rotulagem de Medicamentos
Medicamentos sem Prescrição
[Mh] Termos MeSH secundário: Analgésicos
Antipiréticos
Contraindicações de Medicamentos
Rotulagem de Medicamentos/estatística & dados numéricos
Órgãos Governamentais
Seres Humanos
Ibuprofeno
Japão
Medicamentos sem Prescrição/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Antipyretics); 0 (Nonprescription Drugs); WK2XYI10QM (Ibuprofen)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1248/yakushi.17-00183


  2 / 564 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29221478
[Au] Autor:Shah M; Parveen Z; Khan MR
[Ad] Endereço:Department of Biochemistry, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
[Ti] Título:Evaluation of antioxidant, anti-inflammatory, analgesic and antipyretic activities of the stem bark of Sapindus mukorossi.
[So] Source:BMC Complement Altern Med;17(1):526, 2017 Dec 08.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Saponins are the main constituents of genus Sapindus and have the therapeutic potential for inflammatory disorders. In this study the antioxidant, anti-inflammatory, analgesic and antipyretic potential of the stem bark of soap nut (Sapindus mukorossi) methanol extract and its derived fractions has been investigated. METHODS: Powder of stem bark of the S. mukorossi was extracted with methanol (SMM) and fractionated in order of n-hexane (SMH), chloroform (SMC), ethyl acetate (SME), n-butanol (SMB) and the remaining as aqueous fraction (SMA). Quantitative estimation for the total phenolic and total flavonoid content was carried out in all the extract/fractions. Further, various in vitro antioxidant assays were also performed. Anti-inflammatory (Carrageenan induced paw edema), analgesic (hot plate latency test) and antipyretic (rectal temperature) were determined in Sprague-Dawley rat. RESULTS: Quantitative estimation of total phenolic contents in extract/fractions varied between 252.3 ± 2.41 mg of GAE/g - 594.16 ± 4.3 mg of GAE/g while the total flavonoids estimated were from 11.02 ± 1.3 mg of RUE/g to 96.9 ± 3.2 mg of RUE/g. Standard antioxidant assays such as scavenging of DPPH, hydroxyl radical, nitric oxide, phosphomolybdenum assay, reducing power, inhibition of ß-carotene bleaching, iron chelation activity and inhibition of heat induced protein denaturation indicated the antioxidant potential of the extract/fractions. Carrageenan induced paw edema of rat was effectively inhibited by SMA at 300 mg/kg administration to rat (84.19 ± 1.48%) after 3 h and analgesia (latency time) in hot plate test (55.78 ± 1.22%) after 120 min. SMA at 300 mg/kg distinctly decreased the rectal temperature in brewer's yeast (Saccharomyces cerevisiae) induced pyrexia in rat. CONCLUSION: The resulted obtained in this study suggested the therapeutic importance of stem bark of S. mukorossi in inflammatory related disorders.
[Mh] Termos MeSH primário: Analgésicos/farmacologia
Anti-Inflamatórios/farmacologia
Antioxidantes/farmacologia
Antipiréticos/farmacologia
Extratos Vegetais/farmacologia
Sapindus
[Mh] Termos MeSH secundário: Analgésicos/química
Animais
Anti-Inflamatórios/química
Antioxidantes/química
Antipiréticos/química
Comportamento Animal/efeitos dos fármacos
Compostos de Bifenilo/metabolismo
Temperatura Corporal/efeitos dos fármacos
Edema
Feminino
Flavonoides/química
Flavonoides/farmacologia
Masculino
Picratos/metabolismo
Casca de Planta
Extratos Vegetais/química
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Inflammatory Agents); 0 (Antioxidants); 0 (Antipyretics); 0 (Biphenyl Compounds); 0 (Flavonoids); 0 (Picrates); 0 (Plant Extracts); DFD3H4VGDH (1,1-diphenyl-2-picrylhydrazyl)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171227
[Lr] Data última revisão:
171227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171210
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-017-2042-3


  3 / 564 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28603131
[Au] Autor:Khan MS; Hamid A; Akram M; Mustafa SB; Sami A; Shah SMA; Usmanghani K
[Ad] Endereço:Faculty of Eastern Medicine, Hamdard University, Karachi, Pakistan.
[Ti] Título:Antipyretic potential of herbal coded formulation (Pyrexol).
[So] Source:Pak J Pharm Sci;30(1):195-198, 2017 Jan.
[Is] ISSN:1011-601X
[Cp] País de publicação:Pakistan
[La] Idioma:eng
[Ab] Resumo:The antipyretic effect of the aqueous extract of herbal coded formulation containing equal amount of Salix alba, Emblica officinalis, Glycyrrhiza glabra, Adhatoda vasica, Viola odorata, Thea sinensis, Veleriana officinalis, Foeniculum vulgare, Sisymbrium irrio and Achillea millefolium was investigated using the yeast induced pyrexia model in rabbits. Paracetamol was used as a control group. Rectal temperatures of all rabbits were recorded immediately before the administration of the extract or paracetamol and again at 1 hour, after this, temperature was noted at 1 hrs interval for 5 hrs using digital thermometer. At 240mg/kg dose the extract showed significant reduction in yeast-induced elevated temperature as compared with that of standard drug paracetamol (150mg/kg). It is concluded that herbal coded medicine at a dose of 240mg/kg has marked antipyretic activity in animal models and this strongly supports the ethno pharmacological uses of medicinal plants of this formulation.
[Mh] Termos MeSH primário: Antipiréticos/farmacologia
Regulação da Temperatura Corporal/efeitos dos fármacos
Febre/prevenção & controle
Extratos Vegetais/farmacologia
[Mh] Termos MeSH secundário: Acetaminofen/farmacologia
Animais
Antipiréticos/isolamento & purificação
Antipiréticos/toxicidade
Modelos Animais de Doenças
Feminino
Febre/microbiologia
Febre/fisiopatologia
Dose Letal Mediana
Masculino
Fitoterapia
Extratos Vegetais/isolamento & purificação
Extratos Vegetais/toxicidade
Plantas Medicinais
Coelhos
Fatores de Tempo
Leveduras
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antipyretics); 0 (Plant Extracts); 0 (Pyrexol herbal extract); 362O9ITL9D (Acetaminophen)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE


  4 / 564 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28522405
[Au] Autor:Forray C; Buller R
[Ad] Endereço:Lundbeck Pharmaceuticals LLC, 215 College Road, Paramus, NJ 07652, USA. Electronic address: cafo@lundbeck.com.
[Ti] Título:Challenges and opportunities for the development of new antipsychotic drugs.
[So] Source:Biochem Pharmacol;143:10-24, 2017 Nov 01.
[Is] ISSN:1873-2968
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:In spite of the significant impact that the serendipitous discovery of drugs with antipsychotic properties had on the care of patients with psychotic disorders, there are significant challenges when aiming at therapeutic goals such as remission, recovery, improved health-related quality of life and functioning. The efficacy and effectiveness of existing antipsychotic drugs fail to address the full spectrum of symptoms and functional deficits that currently prevent patients with psychotic disorders from achieving fulfilling lives. The study of the pharmacological mechanism of action has increased our knowledge on molecular targets and brain circuits related to the antipsychotic properties of this drug class. However, our understanding of how these molecular targets and brain circuits relate to other aspects of disease pathophysiology like cognitive impairment and negative symptoms is incomplete although these are significant clinical unmet needs. Currently, there is still an important knowledge gap between psychopathology and pathophysiology in schizophrenia research. This may have contributed to some recent costly failures of large clinical development programs for drugs targeted at glutamatergic function and nicotinic receptors. The lack of success of these pharmacological approaches to achieve clinical validation raises important questions concerning the underlying hypothesis that guided the choice of molecular targets, and about the predictive validity of translational models that supported the rationale for testing these drugs in clinical studies. From a clinical perspective there is a need to more strongly consider the disease heterogeneity linked to the use of the current diagnostic classification of subjects and to the validity of the psychopathological constructs and assessments that are used to assess clinical outcomes. A paradigm shift in the development of drugs for schizophrenia is needed. This will require among other addressing: the shortcomings of a single diagnostic entity; the needs for in depth clinical phenotyping to leverage the findings of schizophrenia genetics and advance the understanding of the disease biology; the symptom domains that are the major sources of disability in order to improve functional outcomes beyond current treatment options. In spite of the progress achieved during the last century the task ahead is still daunting and will require the efforts of scientists and clinicians through inclusive public-private partnerships and consortia to create the scientific basis for new therapeutic approaches to schizophrenia.
[Mh] Termos MeSH primário: Antipiréticos
Antagonistas dos Receptores de Dopamina D2
Descoberta de Drogas/métodos
Esquizofrenia/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antipiréticos/efeitos adversos
Antipiréticos/farmacologia
Antipiréticos/uso terapêutico
Disfunção Cognitiva/induzido quimicamente
Transtorno Depressivo/induzido quimicamente
Antagonistas dos Receptores de Dopamina D2/efeitos adversos
Antagonistas dos Receptores de Dopamina D2/farmacologia
Antagonistas dos Receptores de Dopamina D2/uso terapêutico
Indústria Farmacêutica
Seres Humanos
Transtornos Mentais
Esquizofrenia/genética
Esquizofrenia/metabolismo
Esquizofrenia/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipyretics); 0 (Dopamine D2 Receptor Antagonists)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170520
[St] Status:MEDLINE


  5 / 564 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28403057
[Au] Autor:Paulmann M; Mockenhaupt M
[Ad] Endereço:From the Department of Dermatology, Dokumentationszentrum schwerer Hautreaktionen (dZh), Medical Center-University of Freiburg, Hauptstrasse 7, 79104 Freiburg, Germany.
[Ti] Título:Fever in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases: Laboratory Work-up and Antibiotic Therapy.
[So] Source:Pediatr Infect Dis J;36(5):513-515, 2017 May.
[Is] ISSN:1532-0987
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Fever is a symptom that often accompanies skin eruptions, especially in children. It can be a sign of an infectious condition presenting with exanthems or it may precede an exanthematous eruption. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe reactions affecting skin and mucosa with blisters and erosions. High fever occurs in these conditions, frequently before the skin and/or mucosa is affected.
[Mh] Termos MeSH primário: Vesícula/diagnóstico
Eritema Multiforme/diagnóstico
Febre/diagnóstico
Síndrome de Stevens-Johnson/diagnóstico
[Mh] Termos MeSH secundário: Adolescente
Analgésicos/efeitos adversos
Antibacterianos/uso terapêutico
Antipiréticos/efeitos adversos
Infecções Bacterianas/complicações
Infecções Bacterianas/diagnóstico
Infecções Bacterianas/tratamento farmacológico
Infecções Bacterianas/patologia
Vesícula/tratamento farmacológico
Vesícula/etiologia
Vesícula/patologia
Criança
Diagnóstico Diferencial
Eritema Multiforme/tratamento farmacológico
Eritema Multiforme/etiologia
Eritema Multiforme/patologia
Feminino
Febre/tratamento farmacológico
Febre/etiologia
Febre/patologia
Seres Humanos
Masculino
Membrana Mucosa/patologia
Pele/patologia
Síndrome de Stevens-Johnson/tratamento farmacológico
Síndrome de Stevens-Johnson/etiologia
Síndrome de Stevens-Johnson/patologia
Viroses/complicações
Viroses/diagnóstico
Viroses/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics); 0 (Anti-Bacterial Agents); 0 (Antipyretics)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170420
[Lr] Data última revisão:
170420
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1097/INF.0000000000001571


  6 / 564 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28390086
[Au] Autor:Froes TQ; Melo MCC; Souza GEP; Castilho MS; Soares DM
[Ad] Endereço:Laboratory of Pharmacology of Inflammation and Fever, Faculty of Pharmacy, Federal University of Bahia, Salvador, BA, Brazil.
[Ti] Título:Virtual screening and biological evaluation of novel antipyretic compounds.
[So] Source:Chem Biol Drug Des;90(5):739-752, 2017 Nov.
[Is] ISSN:1747-0285
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Due to the absence of safety of the antipyretics to patients with cardiovascular dysfunction, new targets to treat inflammation have been pursued. mPGES-1 is a promising target because its inhibition would not cause the side-effects related to COX inhibition. To identify novel inhibitors of mPGES-1, we developed a ligand-based pharmacophore model that differentiates true inhibitors from decoys and enlightens the structure-activity relationships for known mPGES-1 inhibitors. The model (four hydrophobic centers, two hydrogen bond acceptor and two hydrogen bond donor points) was employed to select lead-like compounds from ZINC database for in vivo evaluation. Among the 18 compounds selected, five inhibited the fever induced by LPS. The most potent compound (5-(4-fluorophenyl)-3-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-2,3dihydro-1,3,4-oxadiazol-2-one) is active peripherally (i.v.) or centrally (i.c.v.) (82.18% and 112% reduction, respectively) and reduces (69.13%) hypothalamic PGE production, without significant COX-1/2 inhibition. In conclusion, our in silico approach leads to the selection of a compound that presents the chemical features to inhibit mPGES-1 and reduces fever induced by LPS. Furthermore, the in vivo and in vitro results support the hypothesis that its mechanism of action does not depend on COX inhibition. Hence, it can be considered a promising lead compound for antipyretic development, once it would not have the side-effects of COX-1/2 inhibitors.
[Mh] Termos MeSH primário: Antipiréticos/química
Antipiréticos/uso terapêutico
Febre/tratamento farmacológico
Oxidiazóis/química
Oxidiazóis/uso terapêutico
Prostaglandina-E Sintases/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Antipiréticos/farmacologia
Dinoprostona/metabolismo
Descoberta de Drogas
Febre/metabolismo
Seres Humanos
Hipotálamo/efeitos dos fármacos
Hipotálamo/metabolismo
Ligantes
Masculino
Oxidiazóis/farmacologia
Prostaglandina-E Sintases/metabolismo
Relação Quantitativa Estrutura-Atividade
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1,3,4-oxadiazol-2(3H)-one); 0 (Antipyretics); 0 (Ligands); 0 (Oxadiazoles); EC 5.3.99.3 (Prostaglandin-E Synthases); EC 5.3.99.3 (Ptges protein, rat); K7Q1JQR04M (Dinoprostone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170409
[St] Status:MEDLINE
[do] DOI:10.1111/cbdd.12995


  7 / 564 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28366286
[Au] Autor:Fang J; Chen C; Cheng H; Wang R; Ma L
[Ad] Endereço:Intensive Care Unit, Ningbo Fourth Hospital, Zhejiang, China. Electronic address: drfangjunjie@163.com.
[Ti] Título:Effect of paracetamol (acetaminophen) on body temperature in acute stroke: A meta-analysis.
[So] Source:Am J Emerg Med;35(10):1530-1535, 2017 Oct.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The objective of this study was to assess the efficacy of paracetamol (acetaminophen) on body temperature in acute stroke. METHODS: Medline, Cochrane Central Register of Controlled Trials, EMBASE, Chinese BioMedical Literature Database, China National Knowledge Infrastructure, and the World Health Organization (WHO) International Clinical Trials Registry Platform were searched electronically. Relevant journals and references of studies included were hand-searched for randomized controlled trials (RCT) and controlled clinical trials (CCT) regarding the efficacy of paracetamol (acetaminophen) on body temperature in acute stroke. Two reviewers independently performed data extraction and quality assessment. Data were analyzed using RevMan 5.3 software by the Cochrane Collaboration. RESULTS: Five studies were included. To compare the efficacy of paracetamol (acetaminophen) in acute stroke, the pooled RR (Risk Ratio) and its 95% CI of body temperature reduction at 24h from the start of treatment were -0.3 (95% CI: -0.52 to -0.08), with statistical significance (P=0.007). Consistently, the pooled RR (Risk Ratio) and its 95% CI of body temperature at 24h from the start of treatment were -0.22 (-0.29, -0.15), with statistical significance (P<0.00001). When analyzing the body temperature reduction after 5days from the start of treatment, the pooled RR (Risk Ratio) and its 95% CI were 0.04 (95% CI: -0.20 to 0.29), with no statistical significance (P=0.73). For functional outcome (mRS≤2) analysis, the pooled RR and its 95% CI were 1.08 (0.88, 1.32), with no statistical significance (P=0.45). In addition, the difference of serious adverse events between acetaminophen and placebo was 0.86 (95% CI: 0.62 to 1.2), with no statistical significance (P=0.27). CONCLUSION: Acetaminophen was revealed to have some favorable influence in body temperature reduction in acute stroke, but showed no important effect on improving functional outcome and reducing adverse events of patients. WHAT THIS PAPER ADDS: What is already known on this subject? Paracetamol (acetaminophen) is one of the most commonly used antipyretic drugs and has some capability to reduce body temperature through acting on central nervous system. WHAT THIS STUDY ADDS: Acetaminophen showed some capability to decrease body temperature for acute stroke. Acetaminophen could not improve functional outcome and reduce adverse events of patients with acute stroke.
[Mh] Termos MeSH primário: Acetaminofen/farmacologia
Temperatura Corporal/efeitos dos fármacos
Acidente Vascular Cerebral/tratamento farmacológico
[Mh] Termos MeSH secundário: Antipiréticos/farmacologia
Seres Humanos
Acidente Vascular Cerebral/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antipyretics); 362O9ITL9D (Acetaminophen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE


  8 / 564 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28359199
[Au] Autor:Uchida NS; Silva-Filho SE; Aguiar RP; Wiirzler LAM; Cardia GFE; Cavalcante HAO; Silva-Comar FMS; Becker TCA; Silva EL; Bersani-Amado CA; Cuman RKN
[Ad] Endereço:* Department of Pharmacology and Therapeutics, State University of Maringá, 87020-900 Maringá, PR, Brazil.
[Ti] Título:Protective Effect of Cymbopogon citratus Essential Oil in Experimental Model of Acetaminophen-Induced Liver Injury.
[So] Source:Am J Chin Med;45(3):515-532, 2017.
[Is] ISSN:0192-415X
[Cp] País de publicação:Singapore
[La] Idioma:eng
[Ab] Resumo:To investigate the hepatoprotective effect of Cymbopogon citratus or lemongrass essential oil (LGO), it was used in an animal model of acute liver injury induced by acetaminophen (APAP). Swiss mice were pretreated with LGO (125, 250 and 500[Formula: see text]mg/kg) and SLM (standard drug, 200[Formula: see text]mg/kg) for a duration of seven days, followed by the induction of hepatotoxicity of APAP (single dose, 250[Formula: see text]mg/kg). The liver function markers alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamyl transferase were determined to evaluate the hepatoprotective effects of the LGO. The livers were used to determine myeloperoxidase (MPO) activity, nitric oxide (NO) production and histological analysis. The effect of LGO on leukocyte migration was evaluated in vitro. Anti-oxidant activity was performed by assessing the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in vitro. LGO pretreatment decreased significantly the levels of ALT, AST and ALP compared with APAP group. MPO activity and NO production were decreased. The histopathological analysis showed an improved of hepatic lesions in mice after LGO pretreatment. LGO inhibited neutrophil migration and exhibited anti-oxidant activity. Our results suggest that LGO has protective activity against liver toxicity induced by paracetamol.
[Mh] Termos MeSH primário: Acetaminofen/efeitos adversos
Analgésicos não Entorpecentes/efeitos adversos
Antipiréticos/efeitos adversos
Doença Hepática Induzida por Substâncias e Drogas/etiologia
Doença Hepática Induzida por Substâncias e Drogas/prevenção & controle
Cymbopogon/química
Óleos Voláteis/uso terapêutico
Fitoterapia
[Mh] Termos MeSH secundário: Animais
Doença Hepática Induzida por Substâncias e Drogas/tratamento farmacológico
Modelos Animais de Doenças
Masculino
Camundongos
Óleos Voláteis/administração & dosagem
Óleos Voláteis/isolamento & purificação
Óleos Voláteis/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Non-Narcotic); 0 (Antipyretics); 0 (Oils, Volatile); 362O9ITL9D (Acetaminophen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170919
[Lr] Data última revisão:
170919
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170401
[St] Status:MEDLINE
[do] DOI:10.1142/S0192415X17500318


  9 / 564 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28328895
[Au] Autor:Jirkof P
[Ad] Endereço:Division of Surgical Research, University Hospital Zürich, University of Zürich, Zürich, Switzerland.
[Ti] Título:Side effects of pain and analgesia in animal experimentation.
[So] Source:Lab Anim (NY);46(4):123-128, 2017 Mar 22.
[Is] ISSN:1548-4475
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This review highlights selected effects of untreated pain and of widely used analgesics such as opioids, non-steroid anti-inflammatory drugs and antipyretics, to illustrate the relevance of carefully planned, appropriate and controlled analgesia for greater reproducibility in animal experiments involving laboratory rodents.
[Mh] Termos MeSH primário: Analgesia/veterinária
Analgésicos/efeitos adversos
Dor/veterinária
[Mh] Termos MeSH secundário: Analgesia/efeitos adversos
Analgésicos Opioides/efeitos adversos
Animais
Anti-Inflamatórios não Esteroides/efeitos adversos
Antipiréticos/efeitos adversos
Dor/prevenção & controle
Roedores
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Analgesics); 0 (Analgesics, Opioid); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Antipyretics)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170323
[St] Status:MEDLINE
[do] DOI:10.1038/laban.1216


  10 / 564 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:28292797
[Au] Autor:Sakulchit T; Goldman RD
[Ti] Título:Acetaminophen use and asthma in children.
[So] Source:Can Fam Physician;63(3):211-213, 2017 Mar.
[Is] ISSN:1715-5258
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:A child with a history of asthma came to my clinic with acute fever. I have heard that acetaminophen might be associated with exacerbation of asthma. Is it safe if I recommend acetaminophen for this child? Most studies suggest an association between acetaminophen use in children and development of asthma later in childhood. However, several confounding factors in study design might contribute to this positive correlation, and without a prospective controlled trial, confirming this finding is challenging. If children have a known history of asthma, it is likely safe to administer a single dose of acetaminophen without concern of precipitating adverse respiratory symptoms. Regular use of acetaminophen to relieve fever or pain does not seem to exacerbate asthma in children more than ibuprofen does.
[Mh] Termos MeSH primário: Acetaminofen/efeitos adversos
Antipiréticos/efeitos adversos
Asma/induzido quimicamente
Asma/epidemiologia
[Mh] Termos MeSH secundário: Acetaminofen/administração & dosagem
Fatores Etários
Antipiréticos/administração & dosagem
Criança
Pré-Escolar
Progressão da Doença
Relação Dose-Resposta a Droga
Seres Humanos
Lactente
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antipyretics); 362O9ITL9D (Acetaminophen)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170403
[Lr] Data última revisão:
170403
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE



página 1 de 57 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde